Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter To Acquire Chemiluminescent Chemistry Provider Lumigen for $185M

NEW YORK (GenomeWeb News) – Beckman Coulter said yesterday that it has signed an agreement to acquire Lumigen for $185 million.
 
Lumigen, based in Southfield, Mich., provides detection chemistries for clinical diagnostics and life science research. 
 
Beckman Coulter currently uses Lumigen’s proprietary chemiluminescent chemistry for its Access family of immunoassay systems.
 
Sales of Lumigen's chemiluminescent substrate to Beckman Coulter accounted for about 40 percent, or $13.2 million, of Lumigen’s reported 2005 revenues of $33 million.
 
Beckman said that the acquisition will ensure it has continued access to Lumigen's current and future immunochemical and other high-sensitivity testing products.
 
The all-cash deal is expected to close by Nov. 1.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.